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Hepatocyte‐like cells (HLCs) differentiated from human‐induced pluripotent stem
cells offer an alternative platform to primary human hepatocytes (PHHs) for
studying the lipid metabolism of the liver. However, despite their great potential,
the lipid profile of HLCs has not yet been characterized. Here, we comprehensively
studied the lipid profile and fatty acid (FA) metabolism of HLCs and compared them
with the current standard hepatocyte models: HepG2 cells and PHHs. We
differentiated HLCs by five commonly used methods from three cell lines and
thoroughly characterized them by gene and protein expression. HLCs generated by
each method were assessed for their functionality and the ability to synthesize,
elongate, and desaturate FAs. In addition, lipid and FA profiles of HLCs were
investigated by both mass spectrometry and gas chromatography and then
compared with the profiles of PHHs and HepG2 cells. HLCs resembled PHHs by
expressing hepatic markers: secreting albumin, lipoprotein particles, and urea, and
demonstrating similarities in their lipid and FA profile. Unlike HepG2 cells, HLCs
contained low levels of lysophospholipids similar to the content of PHHs.
Furthermore, HLCs were able to efficiently use the exogenous FAs available in
their medium and simultaneously modify simple lipids into more complex ones to
fulfill their needs. In addition, we propose that increasing the polyunsaturated FA
supply of the culture medium may positively affect the lipid profile and functionality
of HLCs. In conclusion, our data showed that HLCs provide a functional and relevant
model to investigate human lipid homeostasis at both molecular and cellular levels.
© 2018 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.
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Abbreviations: APOA1, apolipoprotein A‐I gene; APOB, apolipoprotein B gene; ASGR, asialoglycoprotein receptor; BMP4, bone morphogenic protein 4; CE, cholesteryl ester; Cer, ceramide;
DAG, diacylglycerol; DE, definitive endoderm; EGF, epidermal growth factor; ELOVL, fatty acid elongase; FA, fatty acid; FADS, fatty acid desaturase; FASN, fatty acid synthase;
Gb3, globotriaosylceramide; GCK, Glucokinase; Glc/GalCer, glucosyl/galactosylceramide; GSL, glycosphingolipid; HGF, hepatocyte growth factor; hiPSC, human induced pluripotent stem cell;
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LPL, lysophospholipid; M1, Method 1; M2, Method 2; M3, Method 3; M4, Method 4; M5, Method 5; MUFA, monounsaturated fatty acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine;
PHH, primary human hepatocyte; PI, phosphatidylinositol; PL, phospholipid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; SL, sphingolipid; SM, sphingomyelin;
TAG, triacylglycerol; UGCG, UDP‐glucose ceramide glucosyltransferase.
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1 | INTRODUCTION
The liver plays an important role in the regulation of many
physiological functions of the body, including lipid and carbohydrate
metabolism, glycolytic/urea metabolism, plasma protein synthesis,
and the detoxification of a wide variety of molecules (Si‐Tayeb et al.,
2010). Hepatocytes, which comprise about 70% of the liver’s mass,
originate from the anterior portion of the definitive endoderm (DE),
one of the three embryonic layers (Blouin, Bolender, &Weibel, 1977).
Hepatocytes handle many crucial metabolic functions of the
liver, including the synthesis of lipoproteins, triacylglycerols
(TAGs), cholesterol, and phospholipids (PLs; Gordillo, Evans, &
Gouon‐Evans, 2015).
Primary human hepatocytes (PHHs) are currently considered the
“gold standard” in cell modeling for studying, for example, liver
physiology, toxicity, and lipid homeostasis. Typically, PHHs are
obtained from cadaveric donors, but they are scarce and functionally
heterogeneous, and it is hard to maintain them in a culture. When
cultured, PHHs loose functionality relatively fast, and their liver‐
specific features progressively deteriorate, which particularly ham-
pers long‐term studies (Elaut et al., 2006; Godoy et al., 2013). To
address these limitations, various human hepatoma cell lines,
including HepG2 and Huh7, have been used due to their ease of
handling, unlimited life span, and stable phenotype. Nevertheless,
they do not faithfully mirror the metabolic activities of healthy liver
cells. In fact, the expression levels and profiles of genes involved in
liver‐specific functions are poorly presented in these systems
(Olsavsky et al., 2007). As a result, hepatoma cell lines have failed
to predict the numerous adverse hepatotoxic side effects of new
drugs (Castell, Jover, Martínez‐Jiménez, & Gómez‐Lechón, 2006).
Alternatively, animal models, such as rats and mice, or animal primary
hepatocytes have been widely used to study lipid metabolism and
lipoprotein production in the liver (Kvilekval, Lin, Cheng, & Abumrad,
1994). However, the information gained from murine cells is not fully
translatable to humans, and there are significant differences in lipid
metabolism between the species. Animal models are also expensive
and unsuitable for large‐scale screening. Furthermore, due to
growing ethical concerns, there is an urgent need to reduce the
use of rodents and other animal models in research.
Human‐induced pluripotent stem cells (hiPSCs) provide an
unlimited supply of tissue‐specific differentiated cell types for
disease modeling and cell therapy. Hepatocytes differentiated from
pluripotent stem cells circumvent the problem of the limited
availability of cells faced when working with PHHs. They show very
similar characteristics to PHHs; for instance, they secrete albumin as
well as urea, and to some extent express drug transporters and
cytochrome P450 enzymes (Kia et al., 2012). Unlike rodent
hepatocytes and some human hepatoma cells, these hepatocyte‐like
cells (HLCs) are sensitive to hepatitis C virus infection and support
viral replication similar to PHHs (Schwartz et al., 2012).
Patient‐specific iPSC lines provide us with an advantageous system
of HLCs from patients of different genetic backgrounds, a
prerequisite for the development of personalised medicine.
The generation of hiPSC‐derived HLCs (hiPSC‐HLCs) in large
quantities enables their use in modeling inborn errors of hepatic
metabolism, understanding the molecular basis of liver cell differ-
entiation, studying disease mechanisms, and facilitating drug
discovery and safety. HLCs have already proven to be of great value
in developing novel therapeutics (Medine et al., 2013; Szkolnicka
et al., 2014) and identifying the noncoding micro‐RNAs regulating
human liver damage (Szkolnicka et al., 2016; Yang et al., 2016). HLCs
have also been successfully used as in vitro cell culture systems, for
example, to recapitulate the pathophysiology of familial hypercho-
lesterolemia (Cayo et al., 2012) and human cholesterol homeostasis
(Krueger et al., 2013). Lipid defects are central to the pathogenesis of
many common diseases, such as atherosclerosis (Meikle et al., 2011;
Stübiger et al., 2012) and nonalcoholic fatty liver disease (Ruhanen
et al., 2017; Younossi et al., 2016). Therefore, hiPSC‐HLCs offer a
great platform for investigating the basic mechanisms of lipid
metabolism and its dysregulation in a patient‐specific manner.
However, to date, no detailed studies have yet been performed on
the lipid profile and fatty acid (FA) metabolism of HLCs. To better use
HLCs as a cell model to study the role of molecular lipids in liver
diseases, it is essential to know their lipid profile in relation to actual
human adult liver tissue and to the currently used cell models,
namely PHHs and hepatoma cell lines.
Hepatic differentiation methods have greatly improved over
the last decade, enabling the efficient generation of high quality
HLCs from pluripotent stem cells (Cameron et al., 2015; Hannan,
Segeritz, Touboul, & Vallier, 2013; Hay et al., 2008; Kajiwara et al.,
2012; Si‐Tayeb et al., 2010). Nevertheless, the experimental
details and some differentiation factors differ between the
current protocols, which might affect the phenotype of the HLCs.
To reproduce the physiological conditions of the human liver, it is
crucial to generate functional HLCs that are as similar as possible
to PHHs. In this study, we describe five protocols for generating
HLCs from hiPSCs and comprehensively compare the morphology,
genetics, biochemistry, and functional traits of the HLCs pro-
duced. In addition, we compare the HLCs with the two most
common cell models currently used—PHHs and HepG2 cells—as
well as human liver tissue. Most importantly, the lipid profiles of
HLCs, PHHs, and HepG2 cells are analyzed by both mass
spectrometry (MS) and gas chromatography, and the similarities
and main differences between the cell types are discussed in light
of selected key genes involved in FA metabolism. Finally, the lipid
profile of HLCs is fully characterized, and the potential and
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limitations of HLCs as a model for studying lipid metabolism are
evaluated.
2 | MATERIAL AND METHODS
2.1 | Ethical issues
The study and patient recruitment have been approved by the Ethics
Committee of Tampere University Hospital (approval number:
R12123). All participants providing skin biopsies were adults more
than 18 years old who had signed an informed consent form after
receiving both oral and written descriptions of the study.
2.2 | hiPSC reprogramming and cell culture
Three hiPSC lines (UTA.10100.EURCAs, UTA.11104.EURCAs, and
UTA.11304.EURCCs) were generated directly from the fibroblasts of
three individuals. Pluripotency was induced with the Sendai
reprogramming kit (OCT4, SOX2, KLF4, C‐MYC; CytoTune; Life
Technologies, USA) based on the protocol described by Ohnuki,
Takahashi, Yamanaka, (2009) and Takahashi & Yamanaka, (2006).
hiPSCs were then maintained as described before (Kiamehr et al.,
2017). Details of the hiPSC cell culture are also described in the
Supporting Information.
2.3 | Hepatic differentiation
In all methods except Method 4 (M4), hiPSCs were transferred
from mouse embryonic fibroblasts to GeltrexTM (USA; Cat: A14133‐
01, 1:50 dilution), kept in mTeSR1TM medium, and adapted to the
changed culture conditions for a few passages before commencing
the differentiation. In M4, hiPSCs were adapted on Laminin 521
(BioLamina, Lot: 80104) first, and the differentiation was completed
on Laminin mix 111/521‐coated plates (3:1 ratio, 10 µg/ml). The
hiPSCs used in all methods were at passage 20 or higher before
commencing the differentiation. Three lines were differentiated using
each method, except Method 5 (M5), which was applied to two cell
lines. Figure 1 shows a schematic view of all five methods used in the
study. Details of the five differentiation methods are described in
detail in the Supporting Information.
2.4 | PHHs and HepG2 cells
Cryopreserved PHHs (Cat. No. HMCPIS, Lot. HU8210, USA) were
purchased from Gibco®, and hepatocellular carcinoma cells (HepG2,
ATCC‐HB‐8065, Lot. No. 59947519) were purchased from ATCC™.
Both cells were plated according to the manufacturer’s instructions.
PHHs were cultured in William’s E medium (A1217601, Gibco, USA)
supplemented with cocktail B (Gibco, CM 4000) and dexamethasone,
whereas the HepG2 cells were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% FBS.
2.5 | RT‐polymerase chain reaction
RNA extraction and polymerase chain reaction (PCR) for pluripo-
tency markers (OCT4, NANOG, SOX2, and SSEA4) were performed as
published before (Manzini, Viiri, Marttila, & Aalto‐Setälä, 2015).
2.6 | Quantitative PCR (qPCR) analysis
RNA samples were collected at the hiPSC, DE, and HLC stages, and
RNA was extracted using an RNeasy kit (Qiagen, Germany, Cat. No.
74106). Complementary DNA (cDNA) was generated using a high
capacity cDNA Reverse Transcription kit (Applied Biosystems)
according to the manufacturer’s instructions in the presence of an
RNase inhibitor. cDNA was multiplied either by the Power SYBR
Green PCR Master Mix (Life Technology, Cat. No. 1408470, Austin,
TX) and gene‐specific primers (OCT4, SOX17, FOXA2, AFP, ALB) or by
the TaqMan Universal Master Mix (Applied Biosystems, 4304437,
Austin, TX) and gene‐specific TaqMan probes (APOA1, APOB, FADS1,
FADS2, ELOVL2, ELOVL5, FASN) using the BioRad CFX384 Real‐Time
PCR Detection System. Values were normalized to GAPDH, which
was used as an endogenous control, and relative quantification was
F IGURE 1 A schematic representation of the five hepatic
differentiation protocols used for generating hepatocyte‐like cells
(HLCs). Differentiation in Method 1 and Method 2 (M1 and M2) were
started with hiPSC colonies, in Method 3 and Method 4 (M3 and M4)
with dissociated iPSC single cells, and in Method 5 (M5) with 24 hrs
post‐cultured hiPSCs. Plates in Method 4 (M4) were coated with a mix
of Laminin 111/521 (3:1 ratio) instead of the GeltrexTM used in the
remainder of the methods. hiPSC: human‐induced pluripotent stem
cell [Color figure can be viewed at wileyonlinelibrary.com]
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calculated by the ΔΔCT method (Livak & Schmittgen, 2001). PHH
was used as the reference sample.
First Choice® Human Liver Total RNA (hLTR, Cat. No.
AM7960), purchased from Ambion®, was used as an extra control.
The results from qPCR were compared for the HLCs and the three
reference samples (PHHs, hLTR, and HepG2 cells).
2.7 | Immunostaining
Cells were fixed, stained, and visualized as described before (Kiamehr
et al., 2017). Details are also provided in the Supporting Information.
The percentage of ALB‐positive cells and binuclear HLCs were
calculated manually by counting HLCs in 3–5 stained areas and
calculating the average.
2.8 | low‐density lipoprotein uptake
The ability of the cells to uptake low‐density lipoprotein (LDL) was
evaluated by incubating the HLCs with labeled LDL (Cell‐based assay
kit, Cayman, USA, Cat. No. 10011125) for 4 hr, after which the cells
were imaged by fluorescent microscopy.
2.9 | FACS analysis
To analyze the number of CXCR4‐positive cells, endodermal cells
were detached with Versene (Gibco®, UK), suspended in 3%–5%
bovine serum albumin buffer, stained with a PE‐conjugated CXCR4
antibody (R&D Systems FAB173P, Minneapolis, 10 µl for 106 cells)
for 15min at RT, washed three times, and analyzed using the
AccuriTM C6 device (BD Biosciences).
2.10 | Albumin, urea, and TAG secretion
At the late stage of hepatic differentiation, HLCs were evaluated for
their functionality. The albumin, urea, and TAG content of the
conditioned medium were determined, respectively, with the Human
Albumin ELISA Quantitation kit (Bethyl Laboratory), the Quanti-
ChromTM Urea Assay Kit (BioAssay Systems, USA), and the
Triglyceride Quantification Kit (BioVision Inc., Cat. No. K622‐100,
USA) according to the manufacturers’ instructions. The values were
normalized to cell numbers. The results were then compared with the
data from the PHHs and HepG2 cells, which were cultured in parallel
with the HLCs.
2.11 | Lipid mass spectrometry
2.11.1 | Lipid sample preparation and extraction
Lipids (sphingolipids [SL], cholesterol, glycerolipids, and glyceropho-
spholipids) were extracted from the HLCs by Hamilton Robotics AB
and studied by shotgun lipidomics. The detailed procedure is
described by Kiamehr et al., (2017).
2.11.2 | Mass spectrometric analyses and data
processing
In the shotgun lipidomics (cholesteryl ester [CE], diacylglycerol
[DAG], sphingomyelin [SM], lysophosphatidylcholine [LPC], lysopho-
sphatidylethanolamine [LPE], lysophosphatidylserine, lysophosphati-
dylglycerol, and lysophosphatidylinositol [LPI]), lipid extracts were
analyzed on a hybrid triple quadrupole/linear ion trap mass spectro-
meter (QTRAP 5500) equipped with a robotic nanoflow ion source
(NanoMate, Advion Biosciences Inc., Ithaca, NJ) as described by
Heiskanen, Suoniemi, Ta, Tarasov, & Ekroos, (2013). Molecular lipids
were analyzed in positive ion mode using lipid class‐specific
precursor ion or neutral loss scans (Ekroos, Chernushevich, Simons,
& Shevchenko, 2002; Ekroos et al., 2003).
Sphingolipids (ceramide [Cer], glucosyl/galactosylceramide [Glc/
GalCer], lactosylceramide [LacCer], and globotriaosylceramide [Gb3])
and molecular PLs (phosphatidylcholines [PC], phosphatidylethano-
lamines [PE], and phosphatidylinositols [PI]) were analyzed with a
targeted approach using ultra‐high‐pressure liquid chromatography‐
mass spectrometry (UHPLC‐MS; Merrill, Sullards, Allegood, Kelly, &
Wang, 2005). An analytical Acquity BEH C18, 2.1 × 50mm column
with a particle size of 1.7 µm (Waters, Milford, MA) heated to 60°C
was used. Mobile phases consisted of 10mM ammonium acetate in
water with 0.1% formic acid (solvent A) and 10mM ammonium
acetate in acetonitrile:isopropanol (4:3, v/v) containing 0.1% formic
acid (solvent B). The flow rate was set to 500 µl/min. Sphingolipids
were separated with a 15min linear gradient from 75% B to 100% B,
while molecular PLs were analyzed using a 10min gradient from 75%
B to 80% B. Both sphingolipids and PLs were analyzed on a hybrid
triple quadrupole/linear ion trap mass spectrometer (5500 QTRAP)
equipped with an UHPLC system (CTC HTC PAL autosampler and
Rheos Allegro pump or Shimadzu Nexera X2) using a multiple
reaction monitoring based method in positive ion mode for
sphingolipids and negative ion mode for molecular PLs. Curtain gas
was set at 25; the ion spray voltage was set at 5000 V in positive ion
mode and −4500 V in negative ion mode, and the ion source was
heated to 400°C in positive mode and to 300°C in negative ion mode.
The collision energy was optimized for each lipid class. Identified
lipids were quantified by normalizing against their respective internal
standard (Ejsing et al., 2006) and total protein concentrations in the
cell sample. Total protein concentrations were determined using the
Micro BCA™ Protein Assay Kit (Thermo Scientific Pierce Protein
Research Products) according to the manufacturer’s instructions.
Data processing was performed by MultiQuant, LipidView (AB Sciex)
software and SAS.
2.12 | FA gas chromatography
To confirm our observations from the MS analysis of molecular lipids
and to investigate the effect of the medium on the FA profile of the
cells, the FA composition of HLCs, PHHs, and HepG2 cells and their
media was analyzed by gas chromatography as described in detail
by Kiamehr et al., (2017). Briefly, the acyl chains in the cell pellet
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lipids or the lipid residues of the nitrogen‐dried media were
converted to FA methyl esters (FAMEs) in a transesterification
reaction with 1% methanolic H2SO4. The quantitative analysis of the
FAMEs, which were extracted into hexane, was performed using a
Shimadzu GC‐2010 Plus gas chromatograph with a flame‐ionization
detector, and the FAME structures were identified by Shimadzu
GCMSQP2010 Ultra with a mass selective detector. In both systems,
the components of the FAME mixtures were separated in ZB‐wax
capillary columns (30m, 0.25 mm ID, 0.25 μm film; Phenomenex). The
calculations of the FA compositions and concentrations followed
standard procedures (Kiamehr et al., 2017), and the FAs were
marked by using the abbreviations: [carbon number]:[number of
double bonds] n‐[position of the first double bond calculated from
the methyl end] (e.g., 22:6n‐3).
2.13 | Statistical analysis
GraphPad Prism version 5.02 software was used for the data
analysis. Data are presented as means ± standard deviation with n
representing the number of independent experiments. The results
were compared using one‐way analysis of variance, followed by
Bonferroni’s multiple‐comparison test. A p value < 0.05 was con-
sidered statistically significant.
3 | RESULTS
3.1 | Cell morphology during hepatic
differentiation
In all methods, dramatic morphological changes were observed,
particularly during the first few days of DE differentiation. In all
methods except M5, migrating DE cells possessed a spiky morphol-
ogy, whereas in M5, migrating cells were instead more round or
square‐shaped (Supporting Information Figure S1a). In addition, the
amount of cell death in M5 was considerably lower than in the other
methods. No morphological differences were observed between the
DE cells treated with CHIR 99021 (Method 1, M1) or Wnt3 (Methods
2–4, M2–4). Initiating differentiation with single cells in M3 and M4
did not yield a higher efficiency of DE formation compared with M1
and M2, which were started with colonies (Supporting Information
Figures S1a and S3). However, we did observe cells with a DE
morphology appearing one or even two days earlier in methods
initiated with single cells compared with methods initiated with
colonies (Supporting Information Figure S1a). At the hepatic
specification stage, cells treated with basic fibroblast growth factor,
bone morphogenic protein 4 (BMP4), and hepatocyte growth factor
(HGF; M1) clearly had a different morphology compared with the
cells treated with DMSO (M2–5; Supporting Information Figure S1b),
which might imply different pathways toward hepatoblasts in those
protocols.
Binucleation is a feature of adult hepatocytes and generally
considered a sign of terminal differentiation (Miyaoka & Miyajima,
2013). We found 29% of the PHHs and on average 10% of the HLCs
to be binuclear ( Figures 1b and 2a). The HLCs differentiated by M4
showed the closest binuclearity (16%) to the PHHs. No individual cell
line was shown to be more potent in generating binuclear cells.
3.2 | Characterization of DE and HLCs at the
protein level
hiPSCs expressed OCT4 protein, which was lost during the DE stage,
while the expression of DE markers SOX17 and FOXA2 was
upregulated (Supporting Information Figure S2a). The efficiency of
the DE differentiation, estimated by measuring the CXCR4 expres-
sion by flow cytometry, did not differ across M1, M2, and M3
(Supporting Information Figure S2b). In M4 and M5, the amount of
CXCR4‐positive cells was lower than in the other methods.
The immature hepatic marker AFP was expressed in hepatic
progenitor cells and remained expressed until the later stages in all
five methods (Figure 2a). In addition, ALB, LDL receptor (LDL‐R), and
asialoglycoprotein receptor (ASGR) were all expressed in mature
HLCs (Figure 2a and Supporting Information Figure S5). The average
of the ALB‐positive cells in M1 to M5 was 9.8%, 16.6%, 20.8%, 37.7%,
and 31.5%, respectively, and the percentage in M4 was significantly
higher than in M1, M2, and M3, but not in M5 (Figure 2b). More than
90% of M2‐ to M5‐HLCs were positive for ASGR (data not shown).
3.3 | Gene regulation
As expected, OCT4 was highly expressed at the iPSC stage, whereas
at the DE stage, OCT4 was dramatically downregulated in most of the
cell lines, and SOX17 and FOXA2 were highly expressed (Supporting
Infomation Figure S6). Further differentiation toward HLCs resulted
in significant downregulation of SOX17, whereas FOXA2 remained
upregulated during the rest of the differentiation and maturation of
the HLCs (Figure 2c and Supporting Infomation Figure S7). The HLCs
expressed SOX17 at the same levels as hLTR. The level of FOXA2 in
the HLCs was comparable to those in the reference samples PHH,
hLTR, and HepG2. AFP was upregulated during the early and late
hepatic differentiation stages, indicating the immature characteristic
of the HLCs. The expression of AFP in the M2‐HLCs was statistically
significantly higher than in the M1‐HLCs. ALB was dramatically
upregulated in mature HLCs, up to 2 × 105‐fold compared with that in
the hiPSCs, and its levels remained close but below those found in
the PHHs. The expression of ALB in the M5‐HLCs was significantly
higher than in the M1‐HLCs (p < 0.01) and M3‐HLCs (p < 0.05). The
levels of ALB expression were comparable between the HepG2 and
the PHHs; however, ALB expression was about 19‐fold higher in the
hLTR when compared with the PHHs.
3.4 | Hepatic maturation and functionality
The liver is responsible for producing serum albumin. Therefore, we
evaluated the ability of HLCs to secrete albumin into the conditioned
medium. All HLCs were able to secrete albumin (Figure 2d). Albumin
secretion by UTA.11304 differentiated by M3 was about fourfold
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higher compared with the same cell line differentiated by M1 or M2,
and twofold higher compared with M4 (data not shown), but no other
statistically significant differences were observed between the
differentiation protocols. However, PHHs secreted significantly
larger amounts of albumin than the HLCs or even the HepG2 cells.
The level of secreted urea by the cell lines differentiated by M3
and M4 was considerably higher compared with same lines
differentiated by M1, M2, and M5 and relatively closer to the
amount of urea secreted by the PHHs (Figure 2d). In fact, the level of
urea secreted by the HLCs differentiated by M1, M2, and M5 was
comparable to the HepG2 cells, which secreted 6.5‐fold less urea
than the PHHs.
TAG secretion in the cell lines differentiated by M3, M4, and M5
was at similar levels as in the PHHs (Figure 2d). However, cell lines
differentiated by M1 and M2 secreted, on average, 5.9‐ and 3.8‐fold
more TAG than the PHHs. We were not able to detect secreted TAG
in the HepG2 culture medium due to medium interference.
Apolipoprotein A‐I (APOA1) encodes for apoA, which is the main
protein component of high‐density lipoproteins (HDL). The product
of apolipoprotein B (APOB) is the main protein component of
very‐low‐density lipoprotein (VLDL) and LDL. The expression of both
APOA1 and APOB in the HLCs was comparable to the HepG2 cells,
PHHs, and hLTR, which further indicated the functionality of the
HLCs (Figure 2c). Interestingly, both APOA1 and APOB were
expressed almost 5.5‐fold more in hLTR compared with the PHHs.
All the cell lines were able to uptake the labeled LDL from the
culture medium (Supporting Information Figure S5). This was
confirmed by staining the LDL‐R by monoclonal antibody (Supporting
Information Figure S4).
3.5 | Lipid profiles of HLCs differentiated by
different methods
The HLCs differentiated by M3, M4, and M5 showed superior
functionality as for TAG and urea secretion when compared with M1
and M2. In addition, the M5‐HLCs expressed higher ALB compared
with the HLCs differentiated by M1 and M3. Therefore, we selected
the HLCs differentiated by M3, M4, and M5, analyzed their lipid
profile by MS, and compared their lipid profile. In addition, the lipid
contents of their unconditioned media were studied to investigate
the influence of culture media lipids and their FAs on the cells.
Overall, 15 major lipid classes—including CE, DAG, PC, LPC, PI, LPI,
PE, LPE, SM, Cer, LacCer, Glc/GalCer, and Gb3—were investigated,
and altogether more than 150 molecular species were detected and
studied (Supporting Information Tables S2 and S3).
The lipid profile of the HLCs differentiated by M3, M4, and M5
closely resembled each other ( Figures ). In fact, only the levels of
three PC species (PC 16:1–20:4, PC 17:0–18:1, and PC 17:0–20:4)
were slightly, but statistically significantly, lower in M4 (Figure 3,
marked by blue arrows) compared with the other methods. No other
significant differences were found in any of the molecular species
between the methods. When comparing the total levels of lipid
classes, only Cer was found at significantly lower concentrations in
the cells produced by M5 compared with those produced by M4
(Figure 5b). However, at the molecular species level, none of the Cer
species differed significantly between M4 and M5 (Figure 5a and
Supporting Information Table S2).
3.6 | Lipid profiles of HLCs, PHHs, and HepG2 cells
Next, we compare the lipidomes of the HLCs with the PHHs and
HepG2 cells and describe our findings for each lipid class separately.
In addition, we highlight the differences and similarities between the
PHHs and HepG2 cells.
3.6.1 | Phospholipids
In the HLCs, the molecular species of PC, PE, and PI containing
saturated FAs (SFAs) and monounsaturated FAs (MUFAs) were
mostly similar to those in the PHHs, with the exceptions of PC 18:1/
18:1 (p < 0.05), PC 17:0–18:1 (p < 0.001), and PE 18:0–18:1 (p < 0.05),
which were statistically significantly higher in the HLCs (Figure 3,
marked by red arrows). When the PHHs were compared with the
HepG2 cells, a large number of species showed statistically
significant differences, particularly the species containing 14:0,
16:0, and 18:1 FAs. In PC and PE, the molecular species containing
polyunsaturated FAs (PUFAs) were present in significantly higher
concentrations in the PHHs compared with both the HLCs and
HepG2 cells. This difference was especially pronounced for the
species containing an SFA coupled with FA 18:2 or its derivative 20:4
(e.g., 16:0–18:2, 18:0–18:2, 16:0–18:2, and 18:0–20:4). The HepG2
cells, however, contained more of the species where an MUFA was
F IGURE 2 Characterization and functionality of hiPSC‐derived hepatocyte‐like cells (hiPSC‐HLCs) differentiated from three cell lines by five
methods and their comparison to primary human hepatocytes (PHHs), HepG2 cells, and human liver total RNA (hLTR). (a) Immunostaining of
cells for AFP (red) and ALB (green). Nuclei are stained with DAPI (blue). The red inset on the lower right shows the comparison of the
morphology and binuclearity (red arrows) of M5‐HLCs and PHHs. The scale bar represents 200 µm for the HLCs and 100 µm for the PHHs and
HepG2 cells. (b) The graph on the left shows the average percentage of binuclear HLCs in each method and their comparison to PHHs. The
graph on the right shows the average percentage of ALB‐positive HLCs in each method. Each bar represents the mean ± SD of the manual
counts from the immunostaining image analysis of at least five areas. (c) Real‐time qPCR analysis of the SOX17, FOXA2, AFP, ALB, APOA1, and
APOB genes at the hiPSC and hepatic stage and their comparison to the reference samples. Each sample was run in triplicate and the bars
represent the mean ± SD of three biological replicates from three individual cell lines. The gene expression data were normalized to the
housekeeping gene GAPDH and are presented relative to the PHHs. (d) Biochemical analysis of the conditioned media from the HLCs for
albumin, urea, and triacylglycerol. Values are normalized as 1 million cells per 24 hr. The bars represent the mean ± SD of three biological
replicates of the three cell lines. *p < 0.05, **p < 0.01, ***p < 0.001. DAPI: 6‐diamidino‐2‐phenylindole; n.s.: not significant; qPCR: quantitative
PCR; SD: standard deviation [Color figure can be viewed at wileyonlinelibrary.com]
3750 | KIAMEHR ET AL.
coupled to a PUFA (or another MUFA). The total levels of PC and PI
classes were similar among all three compared cell types. Total PE
was, however, detected at lower levels in the HLCs compared with
the PHHs (statistically significant in M4 and M5 vs the PHHs). This
was mostly due to the higher levels of PE 18:0–18:2 and PE 18:0–
20:4 in the PHHs. The concentration of PC, PE, and PI in the HLC and
PHH media was either zero or negligible, while the HepG2 medium
contained high amounts of PC (12.9 µM) but only minimal amounts of
PE and PI (Supporting Information Figure S7 and Table S3). The
profile and concentration of molecular lysophospholipids (LPLs)—
such as LPC, LPE, and LPI—in the HLCs were very close to those of
the PHHs (Figure 3a). Consequently, the total LPL levels of the HLCs
and PHHs were also similar (Figure 3b). The HepG2 cells, however,
contained considerably higher levels of LPL as total levels and
strikingly high levels of the molecular lyso‐species, with the 18:1 acyl
residue in each LPL class (Figure 3 and Supporting Information
Table S2).
3.6.2 | Neutral lipids
CE concentration was the highest in the HepG2 cells, intermediate in
the HLCs, and the lowest in the PHHs. The CE species profile of the
HLCs and HepG2 cells was different because 16 CE species showed
statistically significantly higher concentrations in the HepG2 cells
F IGURE 3 Lipidomic analysis of phospholipids (PLs) and lysophospholipids (LPLs) in the HLCs differentiated by M3, M4, and M5, and their
comparison to PHH and HepG2 cell lipids. (a) Protein‐normalized concentration of molecular species detected in each class of PLs
(Phosphatidylcholine [PC], phosphatidylinositol [PI], and phosphatidylethanolamine [PE]) as well as LPLs (lysophosphatidylcholine [LPC],
lysophosphatidylinositol [LPI], and lysophosphatidylethanolamine [LPE]). The arrows refer to species that were found to be statistically significantly
different between HLCs in M3, M4, and M5 (blue arrows) or between the HLCs and PHHs (red arrows) by one‐way analysis of variance. (b) Total
concentrations of PLs and LPLs calculated from the sum of all the molecular species in those specific classes. Each sample was run in triplicate and the
bars represent the mean ± standard deviation of the studied cell lines [Color figure can be viewed at wileyonlinelibrary.com]
KIAMEHR ET AL. | 3751
(Figure 4). When interpreting these differences, the effect of medium
CE concentration was considered. The HepG2 medium contained
154 µM of CE, whereas the CE concentrations were negligible in the
HLC and PHH media (Supporting Information Figure S7 and Table S3).
Similar to PLs, the HLCs contained higher levels of DAG species
with FA 18:1 when compared with the PHHs. However, the level of
major DAG species 16:0–18:1 detected in the HLCs was clearly
closer to that detected in the PHHs compared with what was found
in the HepG2 cells. The PHHs, on the other hand, contained higher
levels of DAG species with FA 18:2 (the minor species DAG 18:
1–18:2 being an exception with its equally low levels in the HLCs,
PHHs, and HepG2 cells). As also observed in PC, the DAG species
with relatively short chain FAs (e.g., 14:0, 16:0, and 16:1) were
detected at higher concentrations in the HepG2 cells than in the
HLCs and PHHs (Figure 4A).
3.6.3 | Sphingolipids
Despite higher total SM concentration, HLCs mimicked the SM
profile of PHHs and HepG2 cells, except that SM d18:1/15:0 and SM
d18:1/16:1 were present at statistically significantly higher concen-
trations in the HepG2 cells (Figure 5a). Both the HLCs and HepG2
cells contained significantly higher levels of SM d18:1/16:0 compared
with the PHHs. The level of SM in the HLC and PHH media was
undetectable, whereas the HepG2 medium contained 6.5 µM of SM
(Supporting Information Figure S7 and Table S3).
In terms of the overall SL profile, the HepG2 cells situated
between the PHHs and HLCs. In fact, lipid class data showed that the
HLCs contained lower levels of Cer but higher levels of LacCer, Glc/
GalCer, and Gb3 (members of glycosphingolipid [GSL] family)
compared with the PHHs (Figure 5b). Closer examination showed
that Cers and, particularly, the saturated species with long‐ and very‐
long‐chain FAs (e.g., Cer d18:0/22:0 and Cer d18:1/24:0) were higher
in the PHHs (Figure 5a), in fact, the Cer species profile of the HLCs
resembled more that of the HepG2 cells. On the other hand, the
HLCs contained more GSLs—especially the species d18:1/16:0,
d18:1/24:0, and d18:1/24:1—and the differences were the most
pronounced in the Glc/GalCer class. The HepG2 medium contained
trace amounts of SLs, and the concentration of SLs in the HLC and
PHH media was either negligible or undetectable (Supporting
Information Figure S7 and Table S3).
3.7 | FA analysis
The HLCs contained 15 mol% PUFAs versus 29 mol% and 10.5 mol
% in the PHHs and HepG2 cells, respectively (Figure 6a). The FA
F IGURE 4 Lipidomic analysis of cholesteryl ester (CE) and diacylglycerol (DAG) in the HLCs differentiated by M3, M4, and M5, and their
comparison to PHH and HepG2 cell lipids. (a) Protein‐normalized concentration of molecular species detected for the CE and DAG lipid class. (b)
Total concentrations of CE and DAG calculated from the sum of all the molecular species in those specific classes. Each sample was run in
triplicate and the bars represent the mean ± standard deviation of the studied cell lines [Color figure can be viewed at wileyonlinelibrary.com]
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18:2n‐6 was, in proportion, the highest PUFA detected in the
PHHs (14 mol%); it was also the highest PUFA detected in the PHH
medium (89 mol%; Figure 6b and Supporting Information Table
S3). Both the HLCs and HepG2 cells had a low supply of 18:2n‐6 in
their media and, hence, lower relative levels of 18:2n‐6 in their
cellular FA profile. Interestingly, the HLCs seemed to be able to
compensate for the shortage of supply better than the HepG2
cells, and the levels of 20:4n‐6, a bioactive metabolite of 18:2n‐6,
were only 1.4‐fold lower in the HLCs compared with the PHHs,
indicating an active biosynthesis of 20:4n‐6 from its precursor in
the HLCs.
The total levels of MUFAs in the HLCs (43mol%) were higher
than in the PHHs (25mol%), but they were still lower than in the
HepG2 cells (52 mol%) (Figure 6a). FA 18:1n‐9 (with its 31mol% of all
FAs) was the major MUFA in the HLCs, a reflection of the high
concentration of 18:1n‐9 in their medium. FA 16:1n‐7 (an SCD
Δ9‐desaturation product of 16:0) had the lowest values in the HLCs
(0.6‐fold the PHH level) and the highest values in the HepG2 cells
(1.4‐fold the PHH level). Consequently, the relative concentration of
18:1n‐7 (an fatty acid elongase (ELOVL)5/6 chain elongation product
of 16:1n‐7) was the highest in the HepG2 cells (14mol%) and lower
in HLCs and PHHs (4mol% and 2mol%, respectively). This implies
that the high 18:1n‐7 is a specific feature of HepG2 cells, marking a
clear distinction from the HLCs and PHHs, which appeared similar in
having 18:1n‐9 as their main MUFA component.
The total SFAs in the HLCs, PHHs, and HepG2 cells were 40mol
%, 46mol%, and 37mol%, respectively (Figure 6a). Relative to the
PHHs, the lower SFAs in the HLCs were attributable to the slightly
F IGURE 5 Lipidomic analysis of sphingolipids (SLs) in the HLCs differentiated by M3, M4, and M5, and their comparison to the PHHs and
HepG2 cells. (a) Protein‐normalized concentration of molecular species detected for the sphingomyelin (SM), ceramide (Cer), glucosyl/
galactosylceramide (Glc/GalCer), lactosylceramide (LacCer), and globotriaosylceramide (Gb3) lipid classes. (b) Total concentrations of SLs
calculated from the sum of all the molecular species in those specific classes. Each sample was run in triplicate and the bars represent the
mean ± standard deviation of the studied cell lines. *p ≤ 0.05 [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 6 Fatty acid (FA) analysis (mole% in total FAs) of the M3‐HLCs, PHHs, and HepG2 cells versus their media. (a) Total proportions of
saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), polyunsaturated fatty acids (PUFAs), and dimethyl acetals (DMAs, derived
from plasmalogen PL alkenyl chains) in the studied cell types and their media. The ratio of total unsaturated FAs (UNFAs) to total SFAs is shown
on the top bar. (b) Mirrored bar chart presenting the FA profiles in the M3‐HLCs, PHHs, and HepG2 cells (red bars) in comparison to their media
(blue bars). Each bar represents the mol% of the detected FAs. Error bars in the HLCs are calculated from the mean ± standard deviation of
three biological replicates. (c) Schematic image of the metabolic pathways of SFAs, MUFAs, and PUFAs, including the responsible genes (FASN,
SCD, ELOVL, FADS). The figure is adapted from the work by Glück et al., (2016). HLC: hepatocyte‐like cell; PHH: primary human hepatocyte;
PL: phospholipid [Color figure can be viewed at wileyonlinelibrary.com]
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lower proportion of all major individual FAs (14:0, 16:0, and 18:0).
The lower amount of total SFAs in the HepG2 cells, however, was
mainly due to the considerably lower percentage of 18:0 compared
with the PHHs (2.2‐fold less).
3.8 | Gene expression of key enzymes in FA
metabolism
To further investigate the metabolism of FAs in the HLCs, PHHs,
and HepG2 cells, we studied the expression of five key genes
involved in the synthesis pathways of FA by qPCR. Lipogenesis is
highly affected by glucose homeostasis in the liver. Therefore, the
expression of Glucokinase (encoded by GCK), the key enzyme
involved in glycolysis, was also studied. The results revealed that FA
synthase (FASN), a key gene in de novo FA synthesis, was expressed
in the HLCs mostly at similar levels as in the PHHs (Figure 7a). The
FASN expression level of the HepG2 cells was higher than that of
the PHHs. The expression of GCK in HLCs was at similar levels as in
the PHHs (Figure 7b). Comparing the methods, M3‐HLCs and M4‐
HLCs expressed GCK at statistically significantly higher levels than
M1‐HLCs. FA desaturase 1 (FADS1) was expressed at a statistically
significantly lower level in all the HLCs (p < 0.001) when compared
with the PHHs, but at similar levels as in hLTR and the HepG2 cells.
In the HepG2 cells, hLTR, and almost half of the HLCs, FADS2 was
expressed at lower levels than in the PHHs. In the other half of the
studied HLCs, the expression of FADS2 was similar to that in the
PHHs (Figure 7a). In addition to the FADSs, FA elongases ELOVL2
and ELOVL5, working in sequence with the desaturases, are
essential for the metabolism of long‐chain and highly unsaturated
FAs (Figure 6c). ELOVL2 was expressed in most of the HLC lines at
similar levels to the PHHs, but some lines produced by M2, M3, and
M5 showed statistically significantly higher expression levels
(Figure 7a). The expression of ELOVL2 was statistically significantly
higher in the HepG2 cells than in the PHHs. ELOVL5, on the other
hand, was expressed at roughly similar levels in all analyzed cells
types (PHHs, HepG2 cells, hLTR, and HLCs).
F IGURE 7 Expression levels of genes involved in the metabolism of fatty acids (FAs) (a) and glucose (b). (a) Real‐time qPCR analysis of
ELOVL2, ELOVL5, FADS1, FADS2, and FASN in the HLCs (differentiated by five methods), PHHs, HepG2 cells, and human liver total RNA (hLTR).
(b) Real‐time qPCR analysis of GCK in HLCs (differentiated by five methods), PHHs, HepG2 cells, hiPSCs, and human liver total RNA (hLTR). The
expression of each gene was normalized to the endogenous control gene GAPDH and is presented relative to the PHHs. Each sample was run in
triplicate, and the bars in the HLCs represent the mean ± standard deviation of three biological replicates. PHHs were used as reference group
to calculate the statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001. HLC: hepatocyte‐like cell; PHH: primary human hepatocyte;
qPCR: quantitative PCR
KIAMEHR ET AL. | 3755
4 | DISCUSSION
hiPSC‐HLCs are a promising cell culture platform for studying lipid
homeostasis and its aberrations related to metabolic syndromes
manifested, for example, in atherosclerosis and fatty liver disease. In
the current study, we successfully generated functional HLCs from
hiPSCs using five hepatic differentiation protocols. We then
compared these HLCs comprehensively for gene and protein
expression, lipid composition, and functional traits. Similar compar-
isons were also made with the two common hepatic cell models,
PHHs and HepG2 cells. All five differentiation protocols produced
HLCs capable of expressing ALB, uptaking LDL, and secreting
albumin, urea, and TAG. The lipid profiles of the HLCs, PHHs, and
HepG2 cells were analyzed by both MS and gas chromatography. In
addition, the effects of FA supply from the culture media on the cells’
lipid profile were examined. In this study, we performed, to our
knowledge, the most thorough characterization of the metabolic
traits of HLCs and investigated their potential as a new cell model for
lipid studies in parallel with PHHs and HepG2 cells.
4.1 | Hepatic differentiation
Most protocols for differentiating HLCs from pluripotent stem cells
follow a three‐step differentiation through the DE phase, continuing to
the hepatoblast stage, and finally to mature HLCs. Various growth
factors and cytokines known to be necessary for liver development are
used through these procedures (Cameron et al., 2015; Chen et al.,
2012; Gerbal‐Chaloin et al., 2014; Hannan et al., 2013; Hu & Li, 2015;
Mallanna & Duncan, 2013; Schwartz, Fleming, Khetani, & Bhatia, 2014;
Si‐Tayeb et al., 2010; Sullivan et al., 2010; Takayama et al., 2012). We
observed that at the DE stage, the initial density of the hiPSCs played a
more critical role than the type of DE inducer (e.g., CHIR 99021 or
Wnt3). In fact, high initial cell density in M1, M2, and M5 leads to
remaining undifferentiated colonies, whereas inM3 and M4, this results
in the formation of new dense and undifferentiated areas. On the other
hand, very low initial cell density could lead to highly sparse cells and
consequently unsuccessful differentiation. Hence, it is fundamental to
find the optimal cell density for each cell line in each method.
At the hepatoblast stage, cells in M1 were supplemented with
FGF2 and BMP4, mimicking the stimuli present during liver
development (Rasmussen, 2015). However, in other methods, DMSO
was used instead of FGF2 and BMP4. DMSO has histone deacetylase
inhibitor activity and significantly increases the expression levels of
BMP2 and BMP4 while decreasing the expression levels of stem cell
markers, such as Oct4 (Behbahan et al., 2011; Choi et al., 2015;
Czysz, Minger, & Thomas, 2015; Santos, Figueira‐Coelho, Martins‐
Silva, & Saldanha, 2003). At Day 10, the cells in M1 had clear borders;
they had also formed sinusoidal canaliculi‐like structures (Supporting
Information Figure S1b). However, at the end of the hepatoblast
stage and the beginning of the maturation stage, the cells in M2, M3,
M4, and M5 also eventually gained sinusoidal canaliculi‐like
structures (Supporting Information Figure S3). In addition, small lipid
droplets were clearly visible in the cells in the culture medium
containing DMSO, which could be due to excess of FA supplies in
that medium (Kiamehr et al., 2017).
For the maturation of hepatocytes, HGF and oncostatin M were
used. Epidermal growth factor (EGF) was present only in M3, M4, and
M5. It has been shown that HGF and EGF—two tyrosine kinase
receptor ligands—together decrease the expression of several genes
involved in the metabolism of FAs (Michalopoulos, Bowen, Mulè, &
Luo, 2003). In our study, EGF seemed to affect urea and TAG
secretion but not the albumin secretion of the HLCs. In fact, M3‐,
M4‐, and M5‐HLCs secreted both urea and TAG similarly to the
PHHs, but clearly different from the levels secreted by the M1‐ and
M2‐HLCs (Figure 2D).
It has been proposed that the unnatural microenvironment provided
by current culture systems is partly responsible for the immature
features of HLCs (Godoy et al., 2015), and that coating the culture
plates with a mixture of Laminin 521/111 could further promote HLC
maturation (Cameron et al., 2015). Hence, in M4 we replaced the
Geltrex coating with Laminin 521/111. Even though we did not observe
this coating to improve functionality, it increased the number of ALB‐
positive cells by 82% and the binuclearity of HLCs by 65% compared
with those in M3. In the adult liver, 15%–30% of hepatocytes are
binuclear, and binucleation is usually considered a sign of terminal
differentiation in hepatocytes, even though binuclear hepatocytes are
still able to divide (Miyaoka & Miyajima, 2013). One study suggested
that polyploid cells are more resistant to stressful conditions (Anatskaya
& Vinogradov, 2007). However, the effect of size and number of nuclei
on the hepatocyte function is an intriguing question yet to be answered.
It is well established that the levels of lipoproteins in the serum
have a clear correlation with the risk of atherosclerosis (Moss, 1991).
It has been shown that HLCs produce, secrete, and uptake
cholesterol in vitro and that they robustly express apoprotein genes,
for example, APOA1, APOA2, APOB, APOC, and APOE (Rasmussen,
2015). HLCs also respond to statin treatment in vitro by reducing the
amount of secreted cholesterol (Krueger et al., 2013). Here, we
confirmed that HLCs are capable of uptaking labeled LDL (Supporting
Information Figure S5) as well as expressing APOA1 and APOB at
similar levels compared with PHHs (Figure 2c), which is in line with
findings in other studies (Godoy et al., 2015). APOA1 and APOB gene
expression levels were studied as a surrogate for estimating the HDL
and LDL production levels of HLCs.
Overall, the HLCs differentiated by M3, M4, and M5 showed
superior characteristics for studying the liver function and lipid
metabolism compared with the HLCs differentiated by M1 and M2.
The M3‐, M4‐, and M5‐HLCs secreted TAG at similar levels as the
PHHs. In addition, the M3‐ and M4‐HLCs secreted urea at levels closer
to the PHHs when compared with the HLCs differentiated by other
methods. M4 and M5 produced the most albumin‐positive HLCs, and
the M4‐HLCs showed the highest binuclearity compared with the HLCs
differentiated by the other methods. Furthermore, we observed that
the cell lines differentiated by M5 showed the least variation. This could
be attributed to the application of the STEMdiffTM DE kit at the DE
stage, which resulted in uniform DE differentiation. Because the DE
stage is the key phase in hepatic differentiation, evenly differentiated
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DE cells could result in more uniform hepatic differentiation, reducing
possible variation between cell lines. Nevertheless, it should be
considered that the Laminin coating applied in M4 and the STEMdiffTM
DE kit used in M5 adds to the overall costs of the differentiation and
makes these methods more expensive than, for example, M3.
4.2 | Lipid profiling
PUFAs and their bioactive derivatives play important roles during
cell proliferation and differentiation (Bieberich, 2012; Kim, Kim, Kim,
Kim, & Han, 2009). It has previously been shown that the addition of
certain FAs, such as docosahexaenoic acid (22:6 n‐3) or eicosapen-
taenoic acid (20:5 n‐3), to the media could promote neuronal
differentiation in neuronal stem/progenitor cells through the regula-
tion of the cell cycle (Katakura et al., 2013). Furthermore, a definite
mixture of FAs induces adipocyte‐like differentiation of osteosarco-
ma cells through the activation of peroxisome proliferator‐activated
receptors (Diascro et al., 1998). It is known that the endogenous
capacity of cultured cells to modify PUFAs for their needs can
partially compensate for suboptimal supply from the microenviron-
ment and culture medium (Zhang, Kothapalli, & Brenna, 2016). A
simplified schematic figure of the metabolic pathways of SFAs,
MUFAs, and PUFAs and the genes involved is presented in Figure 6c.
PHHs possess an excellent capacity to metabolize diet‐derived
PUFAs (Sprecher, 2000). Most of our HLC lines expressed the key
enzymes in the metabolism of FAs at similar levels to the PHHs. The
HepG2 cells, however, varied significantly in most of the studied
enzymes compared with the PHHs. This indicates that HLCs are
superior cell models for studying the FA metabolism of the liver
compared with HepG2 cells.
Our analysis revealed that PHHs contain a considerably larger
proportion of PUFAs compared with HLCs and HepG2 cells. The high
percentage of 18:2n‐6 in the PHHs reflects the very rich supply of
18:2n‐6 from the medium, part of which was apparently converted to
20:4n‐6 by the cells using the FADS2, ELOVL5, and FADS1 enzymes.
Even though the 18:2n‐6 level in the HLCs medium was very low,
these cells were able to efficiently produce 20:4n‐6, suggesting the
proper expression of FADS2, ELOV5, and FADS1. Interestingly, the
main n‐3 PUFA, 22:6n‐3, was also detected in the HLCs with levels
only 1.8‐fold lower than in the PHHs, despite only trace amounts of
n‐3PUFAs in their medium. This result means that either the n‐
3PUFAs of HLCs originate from previous conditions (hepatoblast
stage), or alternatively, these cells selectively and efficiently take up
and incorporate 22:6n‐3 into their lipids. The HepG2 cells received
22mol% PUFAs from their medium, whereas the HLCs received only
6mol%. In addition, the HepG2 medium was rich in the total FA
content. Despite this, the relative levels of PUFAs in the HepG2 cells
remained low (11mol%) compared with the levels in the PHHs
(29mol%) and HLCs (15mol%). The overloading of the HepG2 cells
with the medium lipids and the consequent high content of neutral
lipids (harboring fewer PUFAs than the structural PL) of the cells may
have resulted in a relatively PUFA‐poor FA composition in their total
lipids.
In deficient states, endogenous synthesis of the 20:3n‐9 from
18:1n‐9 occurs (Kamada et al., 1999). It is of note that the HLCs and
HepG2 cells both contained 2–3mol% of n‐9 PUFAs (20:2n‐
9 + 20:3n‐9), which means that the cells suffered from essential
PUFA deficiency. The large supply of 18:2n‐6 in the PHH medium,
however, prevented them from producing any significant amounts of
n‐9 PUFAs. PUFAs have been shown to be important in the
maturation and functionality of HLCs (Kiamehr et al., 2017).
Therefore, we propose that providing HLCs with a PUFA‐rich
medium may help to produce HLCs with a lipid profile even closer
to PHHs. A high supply of PUFA to PHHs inhibits their endogenous
MUFA synthesis from SFAs (Ntambi, 1999). Likewise, in our study,
the total MUFA in the PHHs remained low compared to the HLCs
and HepG2 cells. The lower the PUFA totals, the higher the MUFA
totals were at the expense of the SFAs.
Hepatocytes can uptake FAs from the cell culture medium.
Simultaneously, hepatocytes are able to produce FAs by hydro-
lyzing glucose to pyruvate, which links glycolysis to lipogenesis
where pyruvate is used to synthesize FAs through de novo
lipogenesis (Rui, 2014). Glucokinase (encoded by GCK gene) is
central to the glucose homeostasis and is the key enzyme involved
in the first step of glycolysis. Changes in hepatocyte GCK
expression represent an adaptive action to impaired glucose/lipid
metabolism to maintain glucose homeostasis (Massa, Gagliardino,
& Francini, 2011). In our study, there were no significant
differences in the expression of GCK between the HLCs and the
PHHs. However, the HepG2 cells expressed GCK at statistically
significantly lower levels than the PHHs, which is in line with
previous findings at protein level (Wiśniewski, Vildhede, Norén, &
Artursson, 2016). FASN is a major determinant of the capacity of a
tissue to synthesize FAs de novo, and palmitate (16:0) is its
primary product (Figure 6c; Jensen‐Urstad & Semenkovich, 2012).
Again, most HLC lines expressed FASN equally to the PHHs,
whereas the HepG2 cells had clearly higher expression levels. The
high expression of FASN in the HepG2 cells has also been observed
earlier (Huang & Lin, 2012). The relative activities of SCD and
ELOVL dictate whether the metabolism of 16:0 follows the route
16:0–16:1n‐7–18:1n‐7 or the route 16:0–18:0–18:1n‐9 (Glück,
Rupp, & Alter, 2016). In the former route, the SCD activity is
higher than the ELOVL activity, and in the latter route, the ELOVL
activity is higher than the SCD activity. Clearly, among the cells
analyzed, the route forming 18:1n‐7 was the most active in the
HepG2 cells. This feature differentiates the HLCs and HepG2 cells
and shows that the MUFA‐producing pathway in HLCs resembles
that found in PHHs. The elevated cellular contents of 16:1n‐7 and
high SCD activity appear to promote de novo lipogenesis, which
could partially explain the large neutral lipid stores of the HepG2
cells (Hodson & Fielding, 2013).
4.3 | FAs mirrored in molecular species
We observed that the PL species profile of cells was highly affected
by the culture medium. The PHHs’ lipid profile reflected the high
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medium supply of 18:2n‐6, which after uptake was metabolized to
20:4n‐6 and incorporated into the PLs. Consequently, the PLs
composed of 16:0–18:2, 18:0–18:2, 16:0–20:4, and 18:0–20:4 were
abundant in the PHHs. The much lower supply of 18:2n‐6 to the
HLCs and HepG2 cells kept the levels of the above‐mentioned PL
species low. However, the HLCs could still actively synthesize 20:4
and couple this PUFA with SFAs and MUFAs. To compensate for the
overall PUFA deficiency, the HepG2 cells produced more MUFAs
(observed in high levels of 18:1n‐7), which is reflected in species such
as 16:0–18:1 and 18:1/18:1. The HLCs instead compensated for the
PUFA shortage by uptaking 18:1n‐9, which was abundant in their
medium.
In general, the HLCs and HepG2 cells contained lower concen-
trations of Cer and higher concentrations of LacCer, Glc/GalCer, and
Gb3 when compared with the PHHs. Cer synthesis is a complex
process orchestrated by six CerSs (CerS1–CerS6), each of which
synthesizes Cers with distinct FA chain lengths (Cingolani, Futerman,
& Casas, 2016). Cer has important structural and signaling roles
(Gault, Obeid, & Hannun, 2010). It has been shown that at time of
cellular stress, the generation of C16:0‐ceramide via CerS5 is
proapoptotic, whereas synthesis of C24:0‐ceramides via CerS2 is
prosurvival (Mesicek et al., 2010), and the balance between these
long‐ and very‐long‐chain Cers is critical for cellular homeostasis. In
our study, similar levels of d18:1/16:0 were observed in all three cell
types, but the PHHs had significantly higher levels of d18:1/24:0
(Figure 5a). Transferring the PHHs from a physiological environment
to an artificial 2D system could be stressful for them. Therefore, it is
intriguing to speculate whether the survival or antiapoptosis
mechanism is turned on in PHHs. On the other hand, HepG2 cells
might suppress the apoptotic Cer signal by converting Cer to
complex GSLs, leading to lowered levels of Cer in HepG2 cells.
Overall, the interpretation of the observed Cer profile of the studied
cell types is very complicated and demands further studies.
The UDP‐glucose ceramide glucosyltransferase (UGCG) gene
encodes the enzyme UDP‐glucose Cer glucosyltransferase, which
catalyzes the first glycosylation step in the biosynthesis of GSLs. The
product of this reaction is glucosylceramide, which is the core
structure of many GSLs, including Glc/GalCer (Tokuda et al., 2013).
We have previously reported a higher expression of UGCG in HLCs
compared with PHHs (Kiamehr et al., 2017), which correlates well
with our lipidomics findings of high Glc/GalCer in HLCs. In the C24
species of every sphingolipid class, the ratio of the 24:0 species to the
24:1 species was higher in the PHHs than in the HLCs or HepG2 cells.
This may reflect the dominance of 24:1n‐9 over 24:0 in both the HLC
and HepG2 media and the reversed ratio of these trace MUFAs in the
PHH medium.
The PHHs were cultured in a low FA medium. As a result, the
PHHs contained low levels of CE in their cellular lipid profile. Unlike
the PHH cells, the HepG2 cells—which were grown in FA‐rich
medium—accumulated a large amount of the neutral storage lipids
CE and TAG, the latter being represented via its hydrolysis product
DAG. As is normal for cultured cells, the highest CE species was 18:1,
followed by 16:0 and 16:1, and there were also traces of various
other species. In line with the CE profile, the HepG2 cells contained
large amounts of DAG, chiefly 16:0–18:1 and 18:1/18:1. The HLCs
also showed an accumulation of neutral lipids (although milder than
in the HepG2 cells), which is likely due to their treatment with an FA‐
rich medium at the hepatoblast stage (Day 6 to Day 12; Kiamehr
et al., 2017). Therefore, our work reveals the need to revise the
generally overlooked FA content of culture media and to tailor it
according to the HLCs’ needs. In addition, we propose that increasing
the supply of PUFA in the culture medium may positively affect the
lipid profile and functionality of the HLCs.
To our knowledge, this is the first comparative study that
considers the effects of various stimuli from different protocols on
the differentiation and phenotype of HLCs. We are also the first to
show the detailed lipid profile of HLCs and to evaluate their ability to
metabolize FAs. Taken together, HLCs differentiated from hiPSCs
provide the advantage of direct studies of cellular and molecular
mechanisms that regulate lipid homeostasis in the liver. They also
facilitate a novel platform for the discovery, optimization, and study
of the modes of action of molecules modulating key lipids. This
platform would allow the functional assessment of the impact of
genetic variations in developing metabolic diseases, such as athero-
sclerosis.
5 | CONCLUSIONS
HLCs mimicked the lipid profile of PHHs very well and, thus, showed
to be a better liver cell model than HepG2 cells, especially in terms of
their low LPL content. HLCs were capable of metabolizing FAs to
produce C20–22 highly unsaturated FAs to fulfill the complex
biological functions mediated by those FAs. By improving the PUFA
supply in the medium, we can produce HLCs, which can serve as a
powerful and functional cell model to study patient‐specific
mechanisms in lipid aberrations leading to pathological states, such
as atherosclerosis or fatty liver disease.
ACKNOWLEDGEMENTS
This research received funding from the European Commission’s
Seventh Framework Programme [FP7–2007‐2013] under two grant
agreements, HEALTH.2012–3057392 “Personalized diagnostics and
treatment for high risk coronary artery disease” (RiskyCAD), and
HEALTH‐F2–2013‐602222 “Targeting novel lipid pathways for
treatment of cardiovascular disease” (Athero‐Flux). Research funding
was also received from Instrumentarium Science Foundation
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